Medical Uses of Bisphosphonates - Treat osteoporosis, osteitis deformans (Pagets disease of the bone), bone metastasis, multiple myeloma, and other conditions involving fragile bone - Alendronate and risedronate are commonly used for osteoporosis and Pagets disease - Intravenous pamidronate may be used if oral medications are ineffective or cause digestive tract problems - Strontium ranelate or teriparatide are used for refractory disease - Raloxifene may be used instead of bisphosphonates in postmenopausal women - Bisphosphonates recommended as first-line treatment for post-menopausal osteoporosis - Long-term treatment produces anti-fracture and bone mineral density effects - Alendronate reduces the risk of hip, vertebral, and wrist fractures - Zoledronate reduces the risk of hip and vertebral fractures - Risedronate also reduces the risk of hip fractures - Bisphosphonates reduce the risk of fracture and bone pain in breast, lung, and other metastatic cancers, and multiple myeloma - Mixed evidence regarding whether bisphosphonates improve survival in breast cancer - Bisphosphonate treatment may reduce the risk of cancer spreading to the bone in early breast cancer - Bisphosphonates can reduce mortality in multiple myeloma and prostate cancer - Bisphosphonates may be useful in the treatment of complex regional pain syndrome - Used to reduce fracture rates in children with osteogenesis imperfecta - Used to treat otosclerosis by minimizing bone loss - Medronate and oxidronate mixed with radioactive technetium for bone imaging and detection of bone disease - Evidence of bisphosphonate use as a risk factor for atrial fibrillation, but conflicting reports

Adverse Effects and Risks - Common side effects include upset stomach, inflammation, and erosions of the esophagus - Fever and flu-like symptoms may occur after the first infusion of intravenous bisphosphonates - Osteonecrosis of the jaw may occur with high-dose intravenous administration in cancer patients - Severe bone, joint, or musculoskeletal pain reported - Bisphosphonate use may be a risk factor for atrial fibrillation, but no recommendation for alteration in prescribing based on AF concerns - Osteonecrosis of the jaw - Atypical fractures of the femur - Esophageal cancer risk - Gastrointestinal tract cancer risk - Atrial fibrillation risk

Chemistry and Classes - All bisphosphonate drugs have a common phosphorus-carbon-phosphorus backbone. - The name 'bisphosphonate' and the function of the drugs are determined by the two phosphonate groups covalently linked to carbon. - The presence of two phosphonate groups in the molecule gives rise to the term 'bis' in bisphosphonate. - The chemical properties, mode of action, and strength of bisphosphonate drugs are determined by the long side-chain (R) in the molecule. - The short side-chain (R), also known as the hook, mainly influences chemical properties and pharmacokinetics. - Nitrogenous bisphosphonates block the enzyme farnesyl diphosphate synthase (FPPS) in the HMG-CoA reductase pathway. - Bisphosphonates containing isoprene chains at R or R position can specifically inhibit GGPS1. - Disruption of the HMG-CoA reductase pathway prevents the formation of metabolites essential for connecting small proteins to the cell membrane. - Bisphosphonates affect protein prenylation, which can impact osteoclastogenesis, cell survival, and cytoskeletal dynamics. - Statins, another class of drugs that inhibit the HMG-CoA reductase pathway, do not have high affinity for bone surfaces like bisphosphonates.

Pharmacokinetics - Approximately 50% of resorbed or infused bisphosphonates are excreted unchanged by the kidney. - Bisphosphonates have a high affinity for bone tissue and are rapidly adsorbed onto the bone surface. - Once in the bone, bisphosphonates have a very long elimination half-life, which can exceed ten years. - Bisphosphonates accumulate to a high concentration only in bones due to their preference for binding to calcium ions. - The high concentration of bisphosphonates in bones is due to their release by osteoclasts, the bone cells responsible for bone resorption.

History and Development - Bisphosphonates were first investigated in the 1960s for use in bone metabolism disorders. - They were initially used to soften water in irrigation systems for orange groves. - The potential of bisphosphonates in preventing bone loss by preventing the dissolution of hydroxylapatite was the initial rationale for their use in humans. - The actual mechanism of action of bisphosphonates was demonstrated in the 1990s with the launch of alendronate by Merck & Co. - Bisphosphonates have a long history of development and research in the field of bone health. - Safety reviews and updates by regulatory authorities.